INTERPACE BIOSCIENCES, INC. Cash Flow Statement
IDXG|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
INTERPACE BIOSCIENCES, INC. generated $6M in operating cash flow and $5M in free cash flow in FY2025. Free cash flow margin was 14.1% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -2.84 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $24.6M | $6.7M | $1.1M | -$22.0M | -$14.9M | -$26.5M | -$26.7M | -$3.2M | -$12.2M | -$8.3M | -$11.4M | -$16.1M | -$4.6M | -$25.5M | -$11.9M |
| Depreciation & Amortization | $425.0K | $300.0K | $1.0M | $2.6M | $5.4M | $5.5M | $4.5M | $3.5M | $3.7M | $4.5M | $5.0M | $2.4M | $1.4M | $2.0M | $3.0M |
| Operating Cash Flow | $5.8M | $4.6M | $1.5M | -$7.7M | -$8.7M | -$14.0M | -$19.0M | -$8.7M | -$15.3M | -$7.6M | -$19.8M | -$16.4M | -$3.5M | -$10.3M | $2.0M |
| Capital Expenditures | $356.0K | $876.0K | $176.0K | $322.0K | $354.0K | $1.6M | $131.0K | $449.0K | $29.0K | - | $353.0K | $2.9M | $1.8M | $1.1M | $343.0K |
| Free Cash Flow | $5.5M | $3.8M | $1.4M | -$8.0M | -$9.1M | -$15.6M | -$19.1M | -$9.1M | -$15.3M | - | -$20.2M | -$19.2M | -$5.3M | -$11.4M | $1.6M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | $208.0K | $228.0K | $314.0K | $156.0K | $16.0K |
| FCF Margin | 14.1% | 8.0% | 6.6% | -141.1% | -110.7% | -48.0% | -78.8% | -41.7% | -96.2% | - | -214.1% | -16.0% | -3.6% | -9.0% | 1.0% |